The 16th International AHCC(R)
(Active Hexose Correlated Compound) Symposium was held in Sapporo, Japan on
July 26th and 27th. The Symposium hosted by the AHCC Research Association
was attended by over 300 medical doctors and researchers from around the
world that presented and discussed research studies completed with AHCC.
Individuals attending this year's event included representatives from
Harvard Medical School, Yale University School of Medicine and the M.D.
Anderson Cancer Center.
Significant preliminary findings from a Yale School of Medicine
clinical study were presented. Researchers at Yale, in collaboration with
researchers in Japan, have confirmed that AHCC significantly enhances the
immune system in a manner that may prove significant for healthy immune
function and as a cancer preventative for older Americans.
Study participants were normal healthy individuals 50 years or older
and were provided AHCC for 60 days. Scientists measured the production of
two key cytokines -- Interferon (IFN-y) and Tumor Necrosis Factor
(TNF-alpha) -- at the baseline, 30 days and 60 days. These two cytokines
are believed to serve a major role in the body's natural method of
preventing the formation and spread of abnormal and cancerous cells.
Yale researchers then measured the levels of these cytokines in the
blood. Results demonstrated that the production of these cytokines by white
blood cells increased within four weeks of taking the recommended dose of
AHCC. The study also showed that the immune-enhancing effect of AHCC
persisted for at least a month after stopping the daily dose. The results
of this study not only confirmed the efficacy of the compound but also
helped explain one of the mechanisms by which AHCC enhances the immune
system.
The two keynote presentations from researchers in Japan focused on the
value of AHCC in cancer therapy. Professor Emeritus Masuo Hosokawa of
Hokkaido University gave an overview of the completed research on the
effects of AHCC in reducing the side-effects of chemotherapy. The second
keynote featured Professor Emeritus Yasuo Kamiyama of Kansai Medical
University whose research investigated AHCC as a complementary therapy to
pharmaceuticals in post-operative cancer patients along with cancer
patients having additional complications.
A scientific review study soon to be published in the upcoming
Nutritional Reviews Journal was presented by Dr. Barry Ritz of Drexel
University's Department of Biotechnology. The paper gave an overview of the
research studies -- published in peer-reviewed journals -- on the positive
effect of AHCC on the influenza virus, the avian "bird flu" virus (H5N1),
the West Nile virus, the Methicillin-Resistant Staphylococcus aureus
(MRSA), the Klebsiella pnuemoniae and the Candida albicans viruses. It was
reported that supplementation with AHCC modulated immunity and delivered
positive results in response to acute infections.
"AHCC continues to demonstrate its essential role for healthy immune
function," said Fred Pescatore, M.D., M.P.H., of the Center for Integrative
and Complementary Medicine, and medical director for the U.S. AHCC Research
Association in response to the research presented at this year's Symposium.
AHCC has been the subject of over 80 research studies worldwide
including studies completed at Harvard University's Faulkner Hospital, Yale
University and Columbia University Medical Center. Research has
demonstrated that AHCC enhances the immune system by increasing the
activity of white blood cells.
What is AHCC (Active Hexose Correlated Compound)?
AHCC is derived from the hybridization of several subspecies of
medicinal mushroom, cultivated in Japan and then produced from a
specialized manufacturing process. AHCC is the leading immune-enhancing
supplement in Japan and is utilized by over 700 hospitals and healthcare
facilities worldwide as a standard preventative supplement for incoming
patients to help reduce the risk of hospital infections as well as
supporting the body's fight against the formation of abnormal cells.
AHCC is manufactured by Amino Up Chemical Company in Sapporo, Japan and
is distributed in the United States by Maypro Industries. Maypro sells AHCC
to a number of leading supplement companies including Quality of Life
Laboratories, a subsidiary of Maypro.
The AHCC Research Association was founded in 1986 to promote further
study. Each year since 1994, over 300 medical doctors and researchers have
gathered in Sapporo, Japan for the AHCC Research Association Symposium to
share and discuss the latest developments.
To learn more about AHCC, visit the AHCC Research Association Web site
at http://www.ahccresearch.com
These statements have not been evaluated by the Food and Drug
Administration. This product is not intended to diagnose, treat, cure or
mitigate disease.
AHCC Research Association
http://www.ahccresearch.com
Symposium Highlights Yale Study Indicating Role Of AHCC(R) For Immune System Enhancement And As A Promising Cancer Preventative
Published
Published Sat 20 Sep 2008
